These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 9443613)

  • 1. Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats.
    Schellens JH; Van de Vrie W; Loos WJ; Kolker HJ; Verweij J; Stoter G; Durante NM; Eggermont AM
    Cancer Chemother Pharmacol; 1997; 41(1):48-52. PubMed ID: 9443613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model.
    Van de Vrie W; Schellens JH; Loss WJ; Kolker HJ; Verwey J; Stoter G; Durante NM; Eggermont AM
    J Cancer Res Clin Oncol; 1996; 122(7):403-8. PubMed ID: 8690750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug.
    Goedhals L; Bezwoda WR; Abratt RP; Rathgeb F; Goebel KJ; Wurst W
    Int J Clin Pharmacol Ther; 1995 Dec; 33(12):664-9. PubMed ID: 8963484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial.
    Ukena D; Boewer C; Oldenkott B; Rathgeb F; Wurst W; Zech K; Sybrecht GW
    Cancer Chemother Pharmacol; 1995; 36(2):160-4. PubMed ID: 7767953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
    Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
    Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
    Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
    Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
    Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
    Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
    Krukemeyer MG; Krenn V; Jakobs M; Wagner W
    J Surg Res; 2012 Jun; 175(1):35-43. PubMed ID: 21470623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics.
    Lukka PB; Paxton JW; Kestell P; Baguley BC
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):151-60. PubMed ID: 22660735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I.
    Sharkey EM; O'Neill HB; Kavarana MJ; Wang H; Creighton DJ; Sentz DL; Eiseman JL
    Cancer Chemother Pharmacol; 2000; 46(2):156-66. PubMed ID: 10972486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
    Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
    Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
    Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoembolization of lung metastases--pharmacokinetic behaviour of carboplatin in a rat model.
    Pohlen U; Rieger H; Meyer BT; Loddenkemper C; Buhr HJ; Heitland P; Koester HD; Schneider P
    Anticancer Res; 2007; 27(2):809-15. PubMed ID: 17465206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma.
    French RC; Cummings J; MacLellan A; MacPherson JS; Ritchie AA; Smyth JF
    Cancer Chemother Pharmacol; 1993; 32(2):156-61. PubMed ID: 8485810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early spontaneous deficiency of calcitonin renal binding sites in rats with a high incidence of calcitonin-secreting tumors (WAG/Rij).
    Bouizar Z; Rostène WH; Treilhou-Lahille F; Pidoux E; Milhaud G; Moukhtar MS
    Cancer Res; 1987 Jul; 47(13):3595-8. PubMed ID: 3034419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.